Jun 9, 2020Paper

Potentially highly potent drugs for 2019-nCoV

BioRxiv : the Preprint Server for Biology
Duc Duy NguyenGuo-Wei Wei

Abstract

The World Health Organization (WHO) has declared the 2019 novel coronavirus (2019-nCoV) infection outbreak a global health emergency. Currently, there is no effective anti-2019-nCoV medication. The sequence identity of the 3CL proteases of 2019-nCoV and SARS is 96%, which provides a sound foundation for structural-based drug repositioning (SBDR). Based on a SARS 3CL protease X-ray crystal structure, we construct a 3D homology structure of 2019-nCoV 3CL protease. Based on this structure and existing experimental datasets for SARS 3CL protease inhibitors, we develop an SBDR model based on machine learning and mathematics to screen 1465 drugs in the DrugBank that have been approved by the U.S. Food and Drug Administration (FDA). We found that many FDA approved drugs are potentially highly potent to 2019-nCoV.

Citations

Sep 2, 2020·Cardiovascular Drugs and Therapy·Kholoud F Aliter, Rami A Al-Horani
Dec 17, 2020·JMIR Medical Informatics·Hafsa Bareen SyedaFeliciano Yu
Jun 18, 2021·PeerJ. Computer Science·Vijay KumarRobertas Damaševičius

Related Concepts

Related Feeds

BioRxiv & MedRxiv Preprints

BioRxiv and MedRxiv are the preprint servers for biology and health sciences respectively, operated by Cold Spring Harbor Laboratory. Here are the latest preprint articles (which are not peer-reviewed) from BioRxiv and MedRxiv.

Related Papers

BioRxiv : the Preprint Server for Biology
Duc Duy NguyenGuewei Wei
BioRxiv : the Preprint Server for Biology
Duc Duy NguyenGuowei Wei
BioRxiv : the Preprint Server for Biology
Kaifu GaoGuo-Wei Wei
European Radiology
Yueying Pan, Hanxiong Guan
© 2021 Meta ULC. All rights reserved